29 results about "Clotting factor" patented technology

The invention provides double-stranded ribonucleic acid for reducing blood coagulation factor XI expression and a modifier and application of the double-stranded ribonucleic acid. Cell experiment results show that the oligonucleotide duplex can significantly inhibit the expression of the FXI gene, and can be used for developing anticoagulant drugs.

Provided are an siRNA which inhibits plasma coagulation factor XI gene expression, a pharmaceutical composition containing the siRNA, a conjugate, a reagent kit, and a use of the siRNA, the pharmaceutical composition thereof and the conjugate in preparing a drug used for treating and / or preventing thrombotic diseases and ischemic strokes.

The present disclosure describes cyclic peptide inhibitors of Factor XI (FXI), preferably FXIa. Also described are pharmaceutical compositions comprising the cyclic peptides and their use in treating conditions, diseases and / or disorders responsive to FXI, preferably FXIa inhibition, including thrombosis or thrombo-inflammatory conditions.

The present invention relates to a method and apparatus for determining the activity of clotting factors in diluted capillary whole blood, citrated whole blood and citrated plasma. The invention also includes the detection of hemoglobin content in the whole blood sample to correct for clotting time so that the clotting time values are not affected by hemoglobin and hematocrit.

A method and kit are provided for measuring and monitoring a combined effect of an anticoagulant drug on coagulation factors II and X in a patient taking the anticoagulant drug. The method includes adding one or more coagulation reagents with the factor VII to a test sample and determining blood clotability of the test sample by measuring an influence of factors II and X.

Methods of reducing the risk of venous thromboembolism (VTE) in a subject undergoing anticoagulant treatment by selectively depleting Factor V Leiden (FVL) in a subject that is heterozygous for FVL, or replacing FVL in the genome of a subject that is homozygous for FVL with a functional Factor V gene, and methods of identifying a subject undergoing anticoagulant treatment who is at risk of developing VTE are disclosed herein.

To provide nucleic acid sequences, expression vectors (e.g., vector genomes) and plasmids, compositions and viral vectors in which the nucleic acid encodes Factor IX (e.g. human Factor IX).SOLUTION: A nucleic acid sequence encodes human Factor IX protein, where the nucleic acid has a reduced number of CpG di-nucleotides compared to a wild-type sequence encoding human Factor IX.SELECTED DRAWING: None

The present invention relates to bispecific antibodies capable of binding to coagulation Factor IX (FIX) and / or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and / or the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A with or without inhibitors.

The present application belongs to the technical field of blood product preparation, and particularly relates to a method for separating blood coagulation factor VIII and vWF factor from blood plasma. The method comprises the following steps in sequence: after cellulose is balanced, the cellulose is mixed with raw material blood plasma, filtered after stirring, and cellulose precipitate is obtained; after the cellulose precipitate is eluted, the cellulose precipitate is soaked in precipitate dissolving solution, and filtrate is obtained by filtering; the filtrate is subjected to three times of ion exchange chromatography, and factor VIII and / or vWF factor product is obtained. The technical scheme solves the technical problems of the prior art, such as complicated process steps for purifying and enriching human blood coagulation factor VIII and vWF from blood plasma cold precipitate, and unsatisfactory production efficiency and product quality. The cold precipitate protein solution prepared by the method can separate factor VIII, vWF factor and fibrinogen product at the same time through chromatography, improve the utilization rate of plasma protein, and has an ideal application prospect.

The invention relates to the field of natural product chemistry, sugar chemistry and biological medicine, and particularly provides glycosaminoglycan and / or a series of derivatives thereof as well as a preparation method and application of the glycosaminoglycan and / or the series of derivatives thereof, the glycosaminoglycan is extracted from starfish glabrata, and the preparation method comprises the following steps: extracting by adopting a papain combined alkaline hydrolysis method; the invention discloses an ALHX-2M series derivative and application of the ALHX-2M series derivative in prevention or treatment of thrombotic diseases, and the ALHX-2M series derivative is obtained by performing separation and purification through ion exchange column chromatography and molecular exclusion column chromatography to obtain ALHX-2M, and further performing deacetylation, deamination and depolymerization treatment and gel column chromatography separation and purification on the ALHX-2M series derivative and the application of the ALHX-2M series derivative in prevention or treatment of thrombotic diseases. The glycosaminoglycan and the derivative thereof take an endogenous blood coagulation factor X enzyme complex (FXase) as an action target, the anticoagulation activity and the antithrombotic activity of the glycosaminoglycan and the derivative thereof are superior to those of low-molecular-weight heparin, the bleeding risk under the equivalent antithrombotic dosage is remarkably reduced, and the glycosaminoglycan and the derivative thereof can be used for medicines or functional foods for preventing and treating thrombotic cardiovascular and cerebrovascular diseases.

The invention discloses a sea snake tail glycosaminoglycan as well as a derivative, a pharmaceutically acceptable salt, a preparation method and an application of the sea snake tail glycosaminoglycan. The sea snake tail glycosaminoglycan has a structure as shown in a formula (I), is prepared by extracting, separating and purifying the sea snake tail, and is further subjected to deacetylation, carboxyl reduction, peroxidation depolymerization, deacylation and deamination depolymerization and gel column chromatography to obtain various derivatives of the sea snake tail glycosaminoglycan. The glycosaminoglycan compound and the derivative thereof show remarkable anticoagulation and antithrombotic activity, are low in bleeding risk, mainly act on an endogenous blood coagulation factor X enzyme complex (FXase) and a heparin cofactor II (HCII), and can provide a new thought for preparing medicines or functional foods for treating and / or preventing thrombotic diseases.

The preparation method comprises the following steps: adding chitosan and bletilla striata polysaccharide into an acidic aqueous solution, stirring and dissolving to obtain a first solution, and adding alkali and antibacterial and anti-inflammatory particles into the first solution to obtain a first suspension; adding chitosan into an acidic aqueous solution, stirring and dissolving to obtain a second solution, and adding alkali into the second solution to obtain a second suspension; and sequentially adding the second suspension liquid, the nylon film and the first suspension liquid into a mold, and freezing the mold, so that the chitosan random layer formed by the second suspension liquid has a disordered structure, and the chitosan orientation layer formed by the first suspension liquid has an orientation structure. The hemostatic sponge prepared by the invention can quickly absorb blood at a wound part, and chitosan and bletilla striata polysaccharide synergistically activate blood coagulation factors to accelerate blood coagulation; meanwhile, tissue fluid, serum and other liquids are adsorbed to the upper layer by the random layer, red blood cells and the like are blocked in the lower layer by the nylon film, blood clot formation is promoted, and then the hemostasis efficiency is remarkably improved.

Protein molecules comprising a variant factor Xa (fXa) or fragments thereof and the use of such protein molecules in the treatment of disease, such as a thrombin-mediated condition, methods of detecting the presence of fVa and a kit comprising the protein molecules of the invention.

The application relates to urine protein markers for differential diagnosis of acute myocarditis and acute myocardial infarction and application thereof, the protein markers including one or more of tumor necrosis factor receptor superfamily member 1A, blood coagulation factor IX and peroxidase 3. The three markers have strong differential diagnosis ability to patients with acute myocarditis and acute myocardial infarction, thereby providing a new noninvasive differential diagnosis method for the two diseases.

Methods of reducing the risk of venous thromboembolism (VTE) in a subject undergoing anticoagulant treatment by selectively depleting Factor V Leiden (FVL) in a subject that is heterozygous for FVL, or replacing FVL in the genome of a subject that is homozygous for FVL with a functional Factor V gene, and methods of identifying a subject undergoing anticoagulant treatment who is at risk of developing VTE are disclosed herein.

Provided are an siRNA which inhibits plasma coagulation factor XI gene expression, a pharmaceutical composition containing the siRNA, a conjugate, a reagent kit, and a use of the siRNA, the pharmaceutical composition thereof and the conjugate in preparing a drug used for treating and / or preventing thrombotic diseases and ischemic strokes.

The invention belongs to the technical field of biology, and particularly relates to a deep sea anticoagulant peptide, a composition thereof, a preparation method and application of the deep sea anticoagulant peptide in food, health food and medicine. The deep sea anticoagulant peptide is obtained by taking deep sea hippocampal clam as a raw material, crushing, carrying out enzymolysis by adopting pepsin, and carrying out freeze drying. The average molecular weight of the obtained peptide is less than 2000Da, and the peptide has excellent blood coagulation factor XIa inhibitory activity and antithrombotic effect. The deep sea blood coagulation factor XIa inhibitory peptide IFERIAAE is obtained through separation and purification by Sephadex G15 gel chromatography and Sepax GP-C18 reversed-phase chromatography and by utilizing an AlphaFold3-assisted virtual screening technology, and the IC50 of the deep sea blood coagulation factor XIa inhibitory peptide IFERIAAE is 194.9 mu M. The deep sea blood coagulation factor XIa inhibitory peptide IFERIAAE can be used for preparing the deep sea blood coagulation factor XIa inhibitory peptide IFERIAAE. An in-vitro anticoagulation experiment result shows that the peptide can remarkably prolong activated partial thromboplastin time (APTT) and has a remarkable anticoagulation effect. The anticoagulant peptide provided by the invention is derived from deep sea shellfish, is novel in sequence and low in molecular weight, can be used as a template molecule for further modification for research and development of peptide anticoagulant or antithrombotic drugs, and has a wide application prospect.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Coagulation factor VII, CA 19-9, Insulin-like growth factor-binding protein 7, C-X-C motif chemokine 6, and C-C motif chemokine 13 as diagnostic and prognostic biomarkers in renal injuries.

The present invention relates to an improved method for determining the amount of FVIII inhibitors in a patient sample, comprising the provision of a patient plasma sample, a normal pool plasma samples, and a control plasma sample which is FVIII / VWF deficient, inactivating all clotting factors present in the samples, addition of recombinant FVIII (rFVIII) to the control plasma sample, combination of the patient plasma sample with the control plasma sample with rFVIII to obtain a test mixture, and of the normal plasma pool sample with the control plasma sample with rFVIII to obtain a control mixture, incubation of the test mixture and the control mixture for less than 30 minutes, and analyzing the mixtures for residual rFVIII activity in the absence of VWF.

The present disclosure provides double-stranded ribonucleic acids and modifications and uses thereof for reducing expression of coagulation factor XI. Cell experimental results show that the oligonucleotide duplexes of the present disclosure can significantly inhibit the expression of FXI gene, and can be used for developing anticoagulant drugs.

This treatment offers comparable efficacy to existing therapies but with reduced bleeding risk, and provides a safer treatment that can reduce thromboembolic complications of AF, such as stroke, systemic embolism, cognitive decline, and mortality. [Solution] The present invention provides a monoclonal antibody that binds to human coagulation factor XI and XIa (activated factor XI) and its antigen-binding fragment, as well as a pharmaceutical composition containing the same, and a treatment method comprising the step of administering the same.

The present application belongs to the field of biomedical materials, and particularly relates to a coagulation-promoting embolization microsphere and a preparation method thereof. The silk fibroin-based embolization microsphere is prepared creatively, and a silk fibroin film layer on the surface of the microsphere can prevent the risk of coagulation of a catheter in an operation caused by sudden release of thrombin. On the other hand, the silk fibroin in the microsphere has excellent water absorption and lubricity, which is helpful to embolization and prevention of reflux; and the silk fibroin molecule contains a large number of hydroxyl and carboxyl groups, which greatly improves the chelation of coagulation factors and calcium ions. In addition, thrombin factors are loaded in the interior of the microsphere, and calcium ions are chelated on the surface of the microsphere, and the superimposed effect endows the microsphere with rapid embolization capacity, which can effectively accelerate the blood flow blockage of a target blood vessel and prevent reflux. The coagulation-promoting embolization microsphere prepared by the present application is suitable for application in the treatment of brain hypervascular tumors, and can effectively prevent the misblocking of many complex functional blood vessels in the brain caused by reflux.

The invention relates to synthetic liver-specific promoters and expression constructs for producing polypeptides and functional nucleic acids in the liver of a subject. The invention further relates to Factor VIII proteins containing modifications in the amino acid sequence of the Factor VIII protein, as well as nucleic acid constructs encoding the Factor VIII proteins and methods of using these compositions to treat a bleeding disorder.

The invention relates to a composite sponge based on calcium silicate biological ceramic and a preparation method and application thereof, St-Nor and HS-PEG-SH are prepared into a polymer precursor solution, a proper amount of modified anion polysaccharide-sodium alginate is introduced, then the prepared CS is added into the polymer solution, and after foaming treatment, cross-linking curing and freeze drying, the composite sponge based on calcium silicate biological ceramic is obtained. A series of composite sponges based on calcium silicate biological ceramics are obtained, the composite sponges not only have good water absorption capacity and rapid shape recovery capacity, but also have relatively strong mechanical properties, have the potential of expandable hemostatic sponges in incompressible and massive hemorrhage applications, have relatively strong water absorption capacity and macroporous structures, and are suitable for large-scale popularization and application. When the sponge is in contact with blood, blood components such as blood platelets and red blood cells can be effectively enriched, and meanwhile, CS in the sponge plays an important role in accelerating the blood coagulation process. The negative charges in the sponge activate the blood coagulation factor XII and thrombin to trigger the blood coagulation cascade rapid reaction, and further enhance the thrombus strength through the interaction with fibrinogen, so that the sponge has an enhanced hemostatic effect in a massive hemorrhage model and a massive hemorrhage model in a blood dilution state.

The invention belongs to the technical field of medical equipment, and particularly relates to a water temperature and water level integrated control method and device for preparing cryoprecipitation blood coagulation factors, and the method comprises the steps: precisely maintaining the temperature of circulating water at 5-5.5 DEG C through the cooperative operation of a refrigeration system, a main circulating system and a slave circulating system; the equipment comprises the cryoprecipitation blood coagulation factor preparation instrument for executing the method. According to the invention, accurate and cooperative control of water temperature and water level can be realized, the plasma melting time is shortened, the blood coagulation factor VIII activity recovery rate and the product quality are improved, and the equipment operation reliability and safety are improved.

The present disclosure relates to the use of double-stranded ribonucleic acids and modifications, conjugates thereof. The double-stranded ribonucleic acids, modifications and / or conjugates provided by the present disclosure for inhibiting the expression of the coagulation factor XII gene can target and inhibit the expression of coagulation factor XII in fibrotic tissue, thereby preventing and / or treating pulmonary fibrosis, lung injury and asthma.

Provided are recombinant amebocyte clotting factors, their formulation and use in determining the presence and / or amount of a microbial endotoxin in a sample. Also provided is a cartridge containing the recombinant amebocyte clotting factors for determining the presence and / or amount of a microbial endotoxin in a sample.